AgomAb Therapeutics NV (NASDAQ:AGMB) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of AgomAb Therapeutics NV (NASDAQ:AGMB) have been given an average rating of “Moderate Buy” by the six analysts that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $33.00.

Several analysts have issued reports on the stock. B. Riley Financial started coverage on shares of AgomAb Therapeutics in a research report on Thursday, July 23rd. They set a “buy” rating and a $34.00 price target for the company. HC Wainwright started coverage on AgomAb Therapeutics in a research note on Monday, June 22nd. They issued a “buy” rating and a $35.00 target price for the company.

AgomAb Therapeutics Price Performance

Shares of AGMB opened at $15.00 on Tuesday. AgomAb Therapeutics has a fifty-two week low of $8.75 and a fifty-two week high of $17.82. The business has a 50 day simple moving average of $12.31.

AgomAb Therapeutics (NASDAQ:AGMB) last released its earnings results on Thursday, August 6th. The company reported ($0.46) EPS for the quarter. Equities research analysts expect that AgomAb Therapeutics will post -1.84 earnings per share for the current year.

AgomAb Therapeutics Company Profile

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.